Q-omics provides the consensus-scored TRAPPC8 profile across patient tissues and cancer cell-line models. TRAPPC8 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TRAPPC8 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, TRAPPC8 RNA expression shows 20,846 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, COAD, and ACC as cancer lineages where TRAPPC8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAPPC8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAPPC8 survival associations across molecular data types. TRAPPC8 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (9) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAPPC8 RNA expression–survival associations across cancer types. High TRAPPC8 expression shows unfavorable associations in MESO and ACC, but favorable associations in KIRC, LUAD, BRCA and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TRAPPC8 RNA expression.
This table summarizes TRAPPC8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TRAPPC8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAPPC8 shows lower tumor expression in COAD, KIRC, KICH, READ and UCEC and higher tumor expression in CHOL. The COAD box plot shows higher TRAPPC8 RNA expression in normal versus tumor tissue (log2 FC = −0.796, t-test p < 0.001).
This table shows molecular features associated with TRAPPC8 in patient tissues and cancer cell lines. In patient samples, TRAPPC8 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TRAPPC8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
